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On Friday, December 13, 1799, the end of thecentury brought with it the end of the first 
president of the United States: George Washington 
would die in less than 48 hours. His treatment? Mo-
lasses, vinegar, butter, sage tea, calomel, various nat-
ural salves, and the removal of nearly 2.5 liters of his 
blood, or what amounted to about half his total blood 
volume.1,2 While such a treatment regimen may seem 
crude by modern medicinal standards, such was the 
norm since the times of Ancient Greece, when Hip-
pocrates first t heorized t hat t he i mbalance o f f our 
bodily fluids, called “humors,” causes disease. Drain-
ing an excess humor soon became a common medical 
treatment, leading to the phenomenon of bloodlet-
ting and one basis of nearly 2,000 years of medicine.3
Image: Cerebral organoids expressing green fluores-
cent protein. (Dr. Abed Mansour, Gage Lab, The 
Salk Institute).
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But as humanity’s understanding of the world around us—and 
within us—expanded throughout the centuries, so too did our un-
derstanding of disease. Through advancements in microscopy, sci-
entists uncovered a world of microbial organisms concealed within 
the environment, a world largely invisible to the naked eye. With 
the discovery of this microbial world, humorism and other theories 
were replaced by the germ theory of disease. Understanding micro-
organisms, however, solved only part of the problem. Efforts during 
the past century sought to reveal how these disease-causing agents 
interacted with and infected humans, leading to the development of 
cell culture and animal modeling. Yet the fight did not stop there. As 
humanity began to make progress against the foes of the microbial 
worlds, other public health problems emerged. Today, rather than 
succumbing to microorganisms, people die more frequently from 
genetic diseases, cancer, and lifestyle disorders, in part due to in-
creased human life expectancy. Fortunately, by serving as miniatur-
ized models of human organs, organoids may prove to be the gold 
standard for the future of studying disease.
DISEASES IN THE LABORATORY
Currently, diseases are roughly studied in two contexts: cell 
culture and animal models. In cell culture, diseases are modeled by 
infecting or mutating cells and growing them in Petri dishes. Infec-
tion is used when the disease is caused by some external pathogen, 
like a virus, while mutation is used when the disease is caused by 
mistakes in the genetic code, like cancer.4 Animal models operate 
under a similar basis, but animals such as mice or rats are grown 
in cages rather than Petri dishes.5 Treatments, such as novel phar-
maceutical drugs, can then be administered to the diseased cells or 
animals. Theoretically, if treatments are effective in these contexts, 
they are more likely to be effective in humans, generating a treat-
ment development pipeline from cells to animals to clinical trials to 
clinical application.
Practically, this isn’t quite the case. Both cellular and animal 
models suffer from several issues that prevent them from accurately 
forecasting success in clinical trials. Experimental cell lines are dif-
ferent from human cells because replicating cells introduces errors 
in the genome, so modified cell lines that replicate continuously are 
more similar to cancer cells than human cells. Cell cultures are also 
particularly simplistic compared to the human body because cul-
tured cells usually consist of only one cell type (such as kidney cells) 
and exist in 2-D.4 On the other hand, while animals simulate more 
complex conditions, animals and humans exist on different time 
scales of life and differ in factors such as their physical size, metabol-
ic rate, and diet, factors that introduce variation scientists are unable 
to control.6,7 In short, both cell cultures and animal models do not 
accurately model the conditions of the human body, so it isn’t sur-
prising that treatments affect them in different ways than they affect 
humans. Organoids, however, may be an improvement over existing 
non-human models by resolving limitations in both types of models.
c. 400 BC: 
Hippocrates 
began formulating 
humorism, which 
was developed 
further by Galen 
in c. 100 AD.
c. 300 BC: 
Miasma theory 
stemmed from 
humorism; air 
contaminated 
with “miasma” 
was thought to 
cause disease.
c. 300 BC:
Aristotle formal-
ized the theory 
of spontaneous 
generation, 
claiming that 
living organisms 
could be derived 
from nonliving 
matter.
1665:
Robert Hooke dis-
covered the first 
microorganisms 
(fungi).
1668:
Francesco Redi 
began disproving 
spontaneous gen-
eration through 
works with mag-
gots, meat, and 
nets.
1673:
Anton van Leeu-
wenhoek began 
writing about his 
improvements to 
Hooke’s micro-
scopes in 50 years 
of letters to the 
Royal Society of 
London.
1854:
 John Snow iden-
tified the origin 
of the London 
Broad Street 
cholera outbreak, 
contributing to 
his skepticism of 
miasma theory.
1862: 
Louis Pasteur was 
recognized for 
disproving spon-
taneous genera-
tion through his 
swan-necked flask 
experiment, lead-
ing to the advent 
of the germ theory 
of disease.
1890:
Koch published 
his four postu-
lates, which set 
criteria for deter-
mining whether a 
bacterium causes 
a certain disease.
1902:
William Castle 
began studying 
mice for genetic 
work; mice are 
increasingly used 
for biomedical 
research.
1952:
Henrietta Lacks’ 
cells were the first 
human cell line 
to be cultured, 
immortalized in 
memory as the 
HeLa cell line.
1981:
Mina Bissell 
at Lawrence 
Berkeley National 
Laboratory pub-
lished a landmark 
paper leading to 
the rise of 3-D cell 
culture.
Figure 1: A brief timeline of the history of disease and disease modeling.
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HOW TO GROW A BRAIN ORGANOID
Organoids have been defined as “containing several cell types 
that develop from stem cells or organ progenitors and self-organize 
through cell sorting and spatially restricted lineage commitment, 
similar to the process in vivo.”8 Put simply, organoids are grown from 
stem cells, and have three key features: (a) they contain multiple cell 
types specific to the organ they originate from, (b) they can repli-
cate a function of an organ, such as neural activity, and (c) they are 
structurally and spatially similar to an organ.8,9 But how exactly are 
organoids grown and applied in research? Tracing the development 
of a brain organoid from its “birth” may provide insight into this 
question.
A typical brain organoid, like any other organoid, is first grown 
from stem cells, specifically pluripotent stem cells (PSCs). These 
stem cells have the potential to grow into multiple different types of 
cells, hence the name “pluripotent.” These stem cells are seeded into 
a liquid medium and develop into 3-D spherical embryoid bodies, 
which are then transported to a firm matrix made of gel. This matrix, 
which is similar to the human body’s extracellular matrix, contains 
many factors that initiate signalling pathways within the embryoid 
bodies, causing further development and specialization of the PSCs. 
Finally, physical agitation of the embryoid bodies causes them to 
form cavities that resemble ventricles, the neural cavities that contain 
cerebrospinal fluid (CSF). This culture can be maintained for sev-
eral months, during which it begins to resemble a brain even more 
closely: after 6 months, functional synapses can be seen, while after 
more than 9 months, higher-level organization of features such as ac-
tive neuronal networks can be observed. Notably, however, whether 
these networks are similar to those of humans is still uncertain, and 
further research needs to be done to compare the two.10,11,12,13
Cultured brain organoids can model a wide variety of different 
categories of diseases. The causes of some neurological diseases are 
easy to identify, like Sandhoff disease, which is caused by a mutation 
in the HEXB gene leading to a buildup of fats in the central nervous 
system, eventually leading to death. Scientists from the NIH and the 
University of Massachusetts have grown two sets of brain organoids; 
one with the HEXB mutation, the other without. They found that 
the HEXB-mutated organoids showed a buildup of fats similar to 
that in Sandhoff disease and were able to monitor how the disease 
modulated the development and differentiation of the stem cells.14 
Other diseases, such as Alzheimer’s Disease (AD), have causes that 
are more complex. Some features of AD are known, such as a char-
acteristic buildup of amyloid plaques and neurofibrillary tangles. 
Scientists who have grown brain organoids afflicted with AD have 
also observed a similar buildup of amyloid plaques and neurofibril-
lary tangles, demonstrating the potential utility of these organoids 
in accurately testing therapies against AD.15 And, of course, cancers, 
which can affect most organs in the body and are notoriously diffi-
cult to treat, have been modeled by organoids. By inducing muta-
tions in stem cells using technologies like CRISPR-Cas9,16 scientists 
have created brain organoids with features that resemble cancers like 
glioblastomas.17 These models of disease are significantly cheaper 
to produce, easier to organize, and less labor-intensive than animal 
models. Perhaps most importantly, these models more accurate-
ly resemble humans compared to cell culture and animal models, 
demonstrating their superiority to current models of disease.18 And 
as advanced microscopy methods and big data image analytics de-
velop further, permitting better visualization of organoids, organoids 
will play a major role in general live tissue 4-D cell biology of the 
future.19 
Organoid technology, however, isn’t quite the perfect model 
of diseases and treatments yet. Tissues in the human body are sur-
rounded by an extensive vascular network consisting of arteries, 
veins, capillaries, and lymphatic vessels that help feed nutrients to 
cells and remove waste products. The complexity of current vascu-
larization networks created for organoids pale in comparison, and 
the size of organoids are limited in part because they can not be vas-
cularized well enough.20 Body tissues are also bathed in extracellu-
lar fluids that create particular biochemical microenvironments for 
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Figure 2: General brain organoid culture protocol. Growing brain organoids can be generalized to about four steps. First, human pluripotent stem 
cells (PSCs) are cultured in appropriate culture media. These cells can be cultured with feeder cells that provide the stem cells with additional 
nutrients, although feeder-free media such as mTeSR1 have been developed. After some time and the addition of certain enzymes that break the 
physical linkages between the PSCs and the plate they are growing on, the PSCs aggregate into 3-D spheres called embryoid bodies (EBs). Next, 
the embryoid bodies begin differentiating into neural tissue after specific molecular factors are added. Any remaining steps serve to further refine 
the structure of the differentiated EBs. For instance, growing the EBs in Matrigel, a gelatinous matrix produced by mouse cancer cells, promotes 
self-organization of the organoids into layers similar to those in the human brain. Additionally, growing the organoids in bioreactors that periodi-
cally agitate the organoids allow more nutrients to perfuse throughout the organoids, increasing the size limits observed in other types of cultures. 
The protocol described in this paper is only one of many, many ways to culture a brain organoid.
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tissue types, but organoids sometimes lack these environments. The 
brain, for instance, is surrounded by a bath of CSF, but organoids 
that create CSF have not been yet been described in literature. And 
finally, certain developmental cues that guide organ development in 
humans have not been replicated—such as the growth of tissues in 
specific directions on specific axes—so organoids do not quite per-
fectly resemble organ superstructure.21
Interestingly enough, organoids can be derived from patient 
cells. That is, cells can be collected from a patient suffering from 
a genetic condition and grown into organoids, allowing testing of 
medicine without significant risk to the patient.13,14 Organoids could 
therefore possibly be used in a future of personalized medicine, 
when treatment regimens are not only created based on specific 
patient phenotypes, but are also tested and modulated before ever 
being used on patients. Such applications would reduce some of the 
inherent risks of medicine—rather than hoping that treatments will 
be effective for patients, why not just grow some organoids and test 
on those instead?
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“By inducing mutations in stem cells using technologies like CRISPR-Cas9, scientists 
have created brain organoids with features that resemble cancers like glioblastoma.”
